BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 12626761)

  • 1. Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction.
    Schmollinger JC; Vonderheide RH; Hoar KM; Maecker B; Schultze JL; Hodi FS; Soiffer RJ; Jung K; Kuroda MJ; Letvin NL; Greenfield EA; Mihm M; Kutok JL; Dranoff G
    Proc Natl Acad Sci U S A; 2003 Mar; 100(6):3398-403. PubMed ID: 12626761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting melanoma inhibitor of apoptosis protein with cancer immunotherapy.
    Schmollinger JC; Dranoff G
    Apoptosis; 2004 May; 9(3):309-13. PubMed ID: 15258462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma.
    Soiffer R; Lynch T; Mihm M; Jung K; Rhuda C; Schmollinger JC; Hodi FS; Liebster L; Lam P; Mentzer S; Singer S; Tanabe KK; Cosimi AB; Duda R; Sober A; Bhan A; Daley J; Neuberg D; Parry G; Rokovich J; Richards L; Drayer J; Berns A; Clift S; Cohen LK; Mulligan RC; Dranoff G
    Proc Natl Acad Sci U S A; 1998 Oct; 95(22):13141-6. PubMed ID: 9789055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ATP6S1 elicits potent humoral responses associated with immune-mediated tumor destruction.
    Hodi FS; Schmollinger JC; Soiffer RJ; Salgia R; Lynch T; Ritz J; Alyea EP; Yang J; Neuberg D; Mihm M; Dranoff G
    Proc Natl Acad Sci U S A; 2002 May; 99(10):6919-24. PubMed ID: 11983866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma.
    Soiffer R; Hodi FS; Haluska F; Jung K; Gillessen S; Singer S; Tanabe K; Duda R; Mentzer S; Jaklitsch M; Bueno R; Clift S; Hardy S; Neuberg D; Mulligan R; Webb I; Mihm M; Dranoff G
    J Clin Oncol; 2003 Sep; 21(17):3343-50. PubMed ID: 12947071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunity to the melanoma inhibitor of apoptosis protein (ML-IAP; livin) in patients with malignant melanoma.
    Zhou J; Yuen NK; Zhan Q; Velazquez EF; Murphy GF; Giobbie-Hurder A; Hodi FS
    Cancer Immunol Immunother; 2012 May; 61(5):655-65. PubMed ID: 22033581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GM-CSF-secreting melanoma vaccines.
    Dranoff G
    Oncogene; 2003 May; 22(20):3188-92. PubMed ID: 12789295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pilot study of granulocyte-macrophage colony-stimulating factor and interleukin-2 as immune adjuvants for a melanoma peptide vaccine.
    Block MS; Suman VJ; Nevala WK; Kottschade LA; Creagan ET; Kaur JS; Quevedo JF; McWilliams RR; Markovic SN
    Melanoma Res; 2011 Oct; 21(5):438-45. PubMed ID: 21697748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical responses and lymphoid infiltrates in metastatic melanoma following treatment with intralesional GM-CSF.
    Si Z; Hersey P; Coates AS
    Melanoma Res; 1996 Jun; 6(3):247-55. PubMed ID: 8819128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GM-CSF-based cancer vaccines.
    Dranoff G
    Immunol Rev; 2002 Oct; 188():147-54. PubMed ID: 12445288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of immune response against NY-ESO-1 by CHP-NY-ESO-1 vaccination and immune regulation in a melanoma patient.
    Tsuji K; Hamada T; Uenaka A; Wada H; Sato E; Isobe M; Asagoe K; Yamasaki O; Shiku H; Ritter G; Murphy R; Hoffman EW; Old LJ; Nakayama E; Iwatsuki K
    Cancer Immunol Immunother; 2008 Oct; 57(10):1429-37. PubMed ID: 18311489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
    Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
    J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autologous melanoma vaccine induces antitumor and self-reactive immune responses that affect patient survival and depend on MHC class II expression on vaccine cells.
    Lotem M; Machlenkin A; Hamburger T; Nissan A; Kadouri L; Frankenburg S; Gimmon Z; Elias O; David IB; Kuznetz A; Shiloni E; Peretz T
    Clin Cancer Res; 2009 Aug; 15(15):4968-77. PubMed ID: 19602547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aberrant expression and potency as a cancer immunotherapy target of inhibitor of apoptosis protein family, Livin/ML-IAP in lung cancer.
    Hariu H; Hirohashi Y; Torigoe T; Asanuma H; Hariu M; Tamura Y; Aketa K; Nabeta C; Nakanishi K; Kamiguchi K; Mano Y; Kitamura H; Kobayashi J; Tsukahara T; Shijubo N; Sato N
    Clin Cancer Res; 2005 Feb; 11(3):1000-9. PubMed ID: 15709165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF) and autologous melanoma vaccine mediate tumor regression in patients with metastatic melanoma.
    Leong SP; Enders-Zohr P; Zhou YM; Stuntebeck S; Habib FA; Allen RE; Sagebiel RW; Glassberg AB; Lowenberg DW; Hayes FA
    J Immunother; 1999 Mar; 22(2):166-74. PubMed ID: 10093041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical response after intradermal immature dendritic cell vaccination in metastatic melanoma is associated with immune response to particulate antigen.
    Smithers M; O'Connell K; MacFadyen S; Chambers M; Greenwood K; Boyce A; Abdul-Jabbar I; Barker K; Grimmett K; Walpole E; Thomas R
    Cancer Immunol Immunother; 2003 Jan; 52(1):41-52. PubMed ID: 12536239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected Stage II melanoma.
    Weber J; Sondak VK; Scotland R; Phillip R; Wang F; Rubio V; Stuge TB; Groshen SG; Gee C; Jeffery GG; Sian S; Lee PP
    Cancer; 2003 Jan; 97(1):186-200. PubMed ID: 12491520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients.
    Hodi FS; Mihm MC; Soiffer RJ; Haluska FG; Butler M; Seiden MV; Davis T; Henry-Spires R; MacRae S; Willman A; Padera R; Jaklitsch MT; Shankar S; Chen TC; Korman A; Allison JP; Dranoff G
    Proc Natl Acad Sci U S A; 2003 Apr; 100(8):4712-7. PubMed ID: 12682289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concerted potent humoral immune responses to autoantigens are associated with tumor destruction and favorable clinical outcomes without autoimmunity.
    Sittler T; Zhou J; Park J; Yuen NK; Sarantopoulos S; Mollick J; Salgia R; Giobbie-Hurder A; Dranoff G; Hodi FS
    Clin Cancer Res; 2008 Jun; 14(12):3896-905. PubMed ID: 18559611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma.
    Kaufman HL; Kim DW; DeRaffele G; Mitcham J; Coffin RS; Kim-Schulze S
    Ann Surg Oncol; 2010 Mar; 17(3):718-30. PubMed ID: 19915919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.